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Abstract
There is little information concerning the
long term outcome of patients with gastro-
oesophageal reflux disease (GORD). Thus 109
patients with reflux symptoms (33 with erosive
oesophagitis) with a diagnosis of GORD after
clinical evaluation and oesophageal testing
were studied. AU patients were treated with a
stepwise approach: (a) lifestyle changes were
suggested aimed at reducing reflux and
antacids and the prokinetic agent domperidone
were prescribed; (b) H2 blockers were added
after two months when symptoms persisted;
(c) anti-reflux surgery was indicated when
there was no response to (b). Treatment was
adjusted to maintain clinical remission during
follow up. Long term treatment need was
defined as minor when conservative measures
sufficed for proper control, and as major if
daily H2 blockers or surgery were required.
The results showed that one third of the
patients each had initial therapeutic need (a),
(b), and (c). Of 103 patients available for follow
up at three years and 89 at six years, respective
therapeutic needs were minor in 52% and 55%
and major in 48% and 45%. Eighty per cent of
patients in (a), 67% in (b), and 17% in (c)
required only conservative measures at six
years. A decreasing lower oesophageal
sphincter pressure (p<0-001), radiological
reflux (p=0028), and erosive oesophagitis
(p=0-031), but not initial clinical scores, were
independent predictors of major therapeutic
need as shown by multivariate analysis. The
long term outcome of GORD is better than
previously perceived.
(Gut 1994; 35: 8-14)
Gastro-oesophageal reflux disease (GORD) is a
common ailment. A cross sectional survey of
presumably healthy people in the United States
has found that 10% experience heartburn daily
and up to 40% have it at least once a month.'
Indeed, most otherwise healthy heavy con-
sumers of antacids have reflux disease.2
Gastro-esophageal reflux disease is a chronic
disease that requires long term management in
nearly all patients. The conventional medical
treatment begins with modifications of lifestyle
that are aimed at reducing the reflux of gastric
contents into the oesophagus, such as dietary,
alcohol, drug, and tobacco restriction, and eleva-
tion of the bedhead; such measures, together
with appropriate antacid use, are usually effec-
tive for patients with clinically mild GORD,
whereas patients with more frequent or severe
reflux symptoms often require some form of acid
suppressive medication with or without addition
of gastric prokinetic agents.3 Antireflux surgery
is a good alternative treatment for patients who
do not respond well to medical treatment.4
About one third ofthe patients with heartburn
who seek medical care have endoscopic evidence
of oesophagitis,' and therapeutic studies of
GORD have been limited primarily to short term
observations of the effects of single drugs in this
subset of patients, with little or no emphasis on
modifications of lifestyle.6 Recent clinical trials
in patients with oesophagitis suggest that most
patients relapse quickly when treatment is inter-
rupted after healing7-'0; however, a bias toward
more severe cases to enter such trials cannot be
discounted. There is little information about the
long term clinical course of patients with peptic
oesophagitis after diagnosis," and even less on
patients with GORD but no oesophagitis.
The present study was carried out in a con-
secutive series ofoutpatients referred to a gastro-
enterology clinic who sought medical care
because of reflux symptoms and had confirmed
GORD, with and without oesophagitis. The
patients were submitted initially to a stepwise
therapeutic regimen until clinical remission and
were subsequently given maintenance treatment
sufficient for them to feel satisfied. They were
then followed up for up to six years. Our aims
were to devise a rational therapeutic approach to
GORD and to assess the existence of predictive
factors of the long term outcome. The informa-
tion gathered in the study provides a comprehen-
sive evaluation of the efficacy of prolonged
treatment in GORD.
Patients and methods
PATIENTS
One hundred and thirty two consecutive out-
patients who had reflux symptoms (heartburn,
or acid regurgitation, or both) as their main
complaint were prospectively evaluated during a
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five year period (December 1979 to January
1985) at a university affiliated gastroenterology
clinic that receives referrals from community
practitioners and specialists. Patients were
accepted if they had had no treatment with H2
blockers for at least two months. There were 67
women and 65 men, with a mean age of 48
(range, 19-79) years. The main duration of
symptoms was 11 (range, 1-50) years. Patients
with peptic ulcer, prior gastric or oesophageal
surgery, or any medical condition that could
cause or aggravate reflux (scleroderma,
alcoholism) were excluded from the study.
STUDY PROTOCOL
At the initial evaluation a composite clinical
score was constructed for each patient that took
into account the frequency and severity of heart-
burn, regurgitation, and dysphagia. Other
clinical features such as non-cardiac chest pain
and respiratory symptoms were also considered.
All patients were offered diagnostic testing
with barium swallow, fibreoptic endoscopy with
pinch oesophageal biopsies, oesophageal
motility studies, and either standard acid reflux
test without HC1 loading (during the first four
years of patient acquisition) or 24 hour oesopha-
geal pH monitoring (during the last year).
THERAPEUTIC APPROACH
After baseline examination, the patients were
given detailed dietary, alcohol, smoking, drug,
and postural advice.'2 '4 Besides efforts at modi-
fication of lifestyle, all patients were treated with
single doses of an oral prokinetic drug (10 mg
domperidone) before meals in addition to 15 ml
of a liquid antacid preparation (aluminium
hydroxide/magnesium hydroxide mixture with
an in vitro neutralising capacity of 4 0 mmol H+/
ml) six times a day, one hour, and three hours
after meals, for at least two months. Specific
instructions were given to regularly take the
prescribed doses ofantacid even in the absence of
symptoms and to use additional antacid as
needed for symptom relief. After two months,
patients with unimproved symptoms were
treated additionally with standard doses of H2
receptor blockers (cimetidine (1-2 g/day) or
ranitidine (300 mg/day) in divided doses) for
another two months, with treatment extended
for up to six months when symptoms were
unremitting. After this period, and when no
major clinical changes were noted, anti-reflux
surgery was indicated. When patients responded
to pharmacological treatment, the drugs were
progressively tapered to minimal effective
maintenance doses while follow up was con-
tinued. Conversely, drug treatment was scaled
up when symptomatic relapses occurred. The
patient's own assessment of satisfaction or dis-
satisfaction was the main determinant of treat-
ment modifications.
During follow up the patients were evaluated
clinically at regular intervals of one to six
months, depending on the clinical state. At each
visit symptoms, compliance with conservative
treatment, and the consumption of medications
were assessed; advice on dietary, posture, and
other lifestyle changes was reinforced when
necessary. Endoscopies were performed every
six months in patients with erosive oesophagitis
and at least once in those with non-erosive
GORD.
Methods
The scoring system for heartburn, regurgitation,
and dysphagia was established from 0 points (no
symptoms) to 5 points (daily, severe, disabling
symptoms). The maximum clinical score was
thus 15 points. Endoscopic oesophagitis was
graded as follows: 0, none; I, erythema; II, non-
confluent erosions; III, confluent erosions or
circumferential shallow ulcerations; IV, deep
ulcer or stricture. Endoscopic pinch biopsies
were obtained at least 3 cm above the cardia and
evaluated histologically according to standard
criteria.
Manometry to determine mean basal lower
oesophageal sphincter pressure (LOSP) and
peristaltic response to wet swallows were per-
formed as described.'5 A standard acid reflux
test'6 without HC1 loading was carried out at
the end of the oesophageal motility study. In
January 1984 this test was substituted by station-
ary 24 hour oesophageal pH monitoring, which
was performed and interpreted as previously
reported.'7
The diagnosis of GORD was based on a
positive result in at least two of the following
tests: spontaneous reflux ofbarium during radio-
logical studies, erosions or ulcerations of the
oesophageal mucosa at endoscopy, microscopic
oesophagitis on endoscopic biopsy specimens,
LOSP s,7 mm Hg (mean -2 SD of our motility
laboratory controls),'5 pH <4 during a standard
acid reflux test or abnormal reflux by 24 h pH
monitoring.
Because all patients completing the long term
study had a follow up of at least six years,
outcomes were evaluated at three and six years
after entry. Six possible outcomes were defined:
(1) no symptoms or occasional symptoms requir-
ing antacids; (2) sustained remission with fre-
quent consumption of antacids with or without
domperidone alone; (3) seasonal symptoms
requiring full courses of treatment with either
antacids or H2 blockers, with intervening
periods as in outcomes 1 or 2; (4) sustained
remission with daily maintenance doses of H2
blockers; (5) need of uninterrupted treatment
with full dose H2 blockers; (6) anti-reflux pro-
cedure performed. To simplify the expression of
results, outcomes 1 to 3 were grouped together as
'minor therapeutic need' (patients were comfort-
able most of the time utilising simple, inexpen-
TABLE I Results ofdiagnostic studies in 109 patients with
reflux symptoms
Study Diagnosis No (0)
Barium swallow Radiological reflux 40 (37)
Endoscopy Erosive oesophagitis 33 (30)
Oesophageal biopsy Microscopic oesophagitis 97 (89)
Motility studies LOSP <7 mm Hg 46 (42)
SART* (n=89) Positive acid reflux 25 (28)
24 hour pH monitoring
(n=20) Abnormal reflux 18 (90)
*Standard acid reflux test without HCI loading.
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sive therapeutic measures), whereas those
labelled 4 to 6 were pooled as 'major therapeutic
need' (patients required expensive pharmaco-
logical measures, close medical supervision, or
surgery).
EXPRESSION OF RESULTS AND STATISTICAL
ANALYSES
All quantitative data are expressed as means
(SD). The unpaired Student's t test, the non-
parametric test of Mann-Whitney, an analysis of
variance (ANOVA), and the XI test with con-
tinuity correction factor as needed were used
when appropriate to detect any differences
between groups. Statistical significance was
defined at an a risk of5% (p<0O05). Multivariate
statistics following Cox's logistic regression
model'8 was used to detect variables with predic-
tive value; therapeutic need at three years was
the dependent variable and all variables with
predictive value by univariate analysis were
included as independent variables. The statisti-
cal processing of the data for the multivariate
analysis was performed with BMDP software.'9
Results
FINDINGS AT INITIAL EVALUATION
Of the 132 patients initially evaluated, 23 were
excluded for various reasons - namely, gastro-
duodenal ulcer found at barium studies or endo-
scopy (11), refusal to undergo one or more of the
required procedures (seven), and negative
results of oesophageal examinations (five
patients). Thus 109 patients were finally
included in the study (56 women and 53 men; age
50 (13), range 19-77 years).
Twenty seven (25%) patients were cigarette
smokers and 35 (32%) were obese (body mass
index >130). Heartburn was present in 106
(97%), regurgitation in 90 (82%), and dysphagia
in 42 (38%). Fifty nine (54%) patients had
nocturnal symptoms (heartburn or regurgitation
awakening them from sleep) at least once a week.
The mean clinical score was 6 4 (2 7) (range
3-13). A history of relapsing chest pain with
negative cardiac studies was elicited from 21
(19%) patients, whereas 37 (34%) gave a history
of bronchial asthma or chronic cough.
Table I gives the relevant results of oesopha-
geal studies. The barium swallow revealed a
hiatus hernia in 64 patients (60%). The endo-
scopic grading ofoesophagitis was 0, 54 patients;
I, 22 patients; II, 16 patients; III, six patients;
TABLE II Response to initial graded treatment in 107 patients with GORD in relation to
presentingfeatures
Control with Control with Surgery
antacids HI blockers indicated(n=35) (n=37) (n=35)
Sex (F/M) 19/16 18/19 19/16
Age (mean (SD) y) 50(13) 50(14) 50(13)
Clinical score (mean (SD)) 6-2 (2 9) 59 (2-2) 7-1 (29)
Radiological reflux (No (%)) 13 (37) 8 (22) 19 (54)*
Erosive oesophagitis (No (%)) 5 (14) 12 (32) 16 (46)t
LOSP (mean (SD) mm Hg) 12-3 (7 0) 111 (6 8) 7 0 (4 9)t
*p=0 009 v H2 blocker group; tp=0 004 v antacid group; tp=0-001 by analysis of variance.
and IV, 11 patients (stricture, seven patients;
deep ulcer, four patients, one of whom had
Barrett's epithelium).
Symptom severity was unrelated to either the
degree of endoscopic oesophagitis or to LOSP.
On the other hand, 20 of 33 (61%) patients with
erosive oesophagitis had a basal LOSP 67 mm
Hg whereas only 27 of 76 (36%) with non-erosive
GORD had abnormally low values (p0=0 15).
RESULTS OF INITIAL, GRADED TREATMENT
Two patients voluntarily withdrew before com-
pleting the initial phase of medical treatment.
Table II shows the response to treatment in
relation to the clinical score, the presence of
oesophagitis, and LOSP in the remaining 107
patients. About two thirds of the patients
responded well to medical treatment; nearly half
of them were well controlled with simple pro-
kinetic plus antacid treatment, whereas the other
half required addition of H2 blockers. Age, sex,
smoking, obesity, and other clinical variables
were unrelated to outcome. Whereas initial
symptom severity did not predict the response,
patients refractory to treatment were more likely
to have both erosive oesophagitis and a lower
LOSP than those with a good response (Table
II). Among the non-responders there were 16 of
33 (49%) patients with erosive oesophagitis, 22 of
45 (49%) with LOSP -7 mm Hg, and 12 of 19
(63%) with both abnormalities.
OUTCOMES DURING FOLLOW UP
The follow up time for the 107 patients complet-
ing the initial treatment phase is close to seven
years (83 (30), range 6-136 months).
Withdrawals and deaths
Four patients (three deaths) were lost to follow
up during the first three years, 12 additional
patients withdrew from the study between the
third and sixth year, and two deaths occurred
during this period. All deaths were unrelated to
GORD.
Side effects ofmedical treatment
Raising the head of the bed caused some prob-
lems for 12 patients. Eight of them repeatedly
slipped off the end of the bed during the night;
these difficulties were overcome by substituting
cotton or wool garments for the original silk or
nylon ones. Four patients had impaired venous
circulation in the lower extremities and required
an additional leg raising device for the night.
Domperidone was universally well tolerated.
Changes in bowel motions (either diarrhoea or
constipation) attributable to antacid use were
reported by 11 patients; they were solved by
judicious substitution of equivalent aluminium
hydroxide or magnesium hydroxide prepara-
tions for some of the doses of the original
mixture. A 79 year old woman with borderline
impaired renal function developed reversible,
high output renal failure four weeks after start-
ing treatment with 1200mg cimetidine a day. No
side effects occurred with ranitidine.
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TABLE III Clinical state of107 patients with GORD after
long term follow up
At3years At 6years
Treatment needs (No (%)) (No (%))
Well with conservative treatment:
Symptom free or occasional AA 17 (16-5) 20 (22-5)
Frequent use ofAA 21 (20 4) 15 (16-9)
Seasonal AA or anti-H2 16 (15-5) 14 (15-7)
Continuous treatment required:
Maintenance anti-H2 17 (16-5) 10 (11-2)
Full/scaled up anti-H2 doses 9 (8.7)* 7 (7*9)t
Antireflux surgery 23 (22 3) 23 (25 8)
Totalt 103 (96 3)§ 89 (83 2)§
*Four patients required ranitidine (600 mg/day) for proper
control; tfour patients required omeprazole (20 mg/day) for good
control; tnumber of patients available at each follow up period;
Spercentage of patients completing the initial treatment protocol(n= 107); AA=antacids; anti-H2=histamine H2 blockers.
Anti-reflux surgery
Anti-reflux surgery was eventually carried out in
23 of 35 (66%) patients not responding to initial
medical treatment, including 13 of 33 (39%)
patients and 10 of 74 (14%) patients with and
without oesophagitis, respectively. The reasons
for not operating on the remaining 12 patients
with refractory GORD were patient's refusal
(n= 10) and high surgical risk (n=2). A Nissen
fundoplication was performed in 21 patients,
whereas in the other two patients an antrectomy
and Y de Roux procedure was selected as the
surgical technique of choice because of the
existence of a peptic stricture with shortened
oesophagus. All surgical repairs were performed
within the first three years (14 (6), range 3-24
months) after the initial evaluation.
Long term outcome
Whereas two thirds of the patients had initially
required H2 blockers, 52% and 55% of those
available for follow up at three and six years,
respectively, fared well with a conservative
approach (Table III). Anti-reflux surgery
resulted in long lasting remission ofreflux symp-
toms in 22 of 23 patients who were operated on
and who have been followed up for 72 (15), range
54-1 16 months.
Table IV shows the treatment needs during
long term follow up in relation to the outcome of
initial, graded treatment. Nearly all patients who
had a good initial response to domperidone plus
antacids were well controlled with conservative
measures at three and six years, and the same
applied to nearly two thirds of those who had
required H2 blockers at the outset.
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Oesophagitis grade
Relation oflower oesophageal sphincter pressure (LOSP) to
the endoscopic grading ofoesophagitis in 103 patients with
gastro-oesophageal reflux disease divided into two groups with
different treatment requirements after afollow up ofthree
years: open circles, well with conservative treatment; closed
circles, needing daily H2-blockers or anti-reflux surgery.
Long term treatment needs differed in
patients with or without oesophagitis at entry
(Table V). It is worth noting that one third of the
patients with oesophagitis had a prolonged
clinical remission with conservative measures
alone, whereas slightly more than one third of
those with non-erosive GORD needed more
aggressive treatment for appropriate long term
control.
Oesophagitis was healed at follow up endo-
scopy in the 13 patients operated on and in 10
medically treated patients; minimal oesophageal
erosions remained for periods of up to two years
in seven other patients who were otherwise in
clinical remission with maintenance treatment.
Follow up endoscopies in patients who entered
the study without erosive oesophagitis showed
normal oesophageal mucosa in all but two
patients out of 73 available at three years and 63
at six years.
Predictive factors
Because patients with worse GORD underwent
anti-reflux surgery early after entry and, except
for a single patient with surgical failure, they
were no longer under active treatment beyond
three years, the analysis of possible predictive
factors ofoutcome has been performed consider-
ing the clinical state of the patients at the three
year assessment.
TABLE IV Treatment requirementsfor symptom control ofpatients with GORD duringfollow up according to the response to
initial treatment
Treatment requirements
At3years At 6years
Response to initial treatment Antacids* Anti-H2t Operated Lost Antacids* Anti-H2ft Operatedt Lost
Antacids (n=35) 28 (85) 3 (9) 2 (6) 2 24 (80) 4 (13) 2 (7) 5
H2 blockers (n=37) 23 (64) 11 (30) 2 (6) 1 20 (66 5) 8 (26-5) 2 (7) 7
Refractory to treatment (n=35) 3 (9) 12 (35) 19 (56) 1 5 (17) 5 (17) 19 (66) 6
Total (n= 107) 54 (53) 26 (25) 23 (22) 4 49 (55) 17 (19) 23 (26) 18
Data are expressed as No (%) of patients available for evaluation at each time period.
*Symptom free with lifestyle modifications and either prn or frequent antacid consumption or with seasonal symptoms only.
tRequiring uninterrupted treatment with H2 blockers at either maintenance or stepped up doses.
tNo further patients underwent anti-reflux surgery after three years and none was lost from follow up.
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TABLE V Treatment requirements duringfollow up according to the presence or absence ofoesophagitis at the outset
Treatment requirements
At3years At6years
Erosive oesophagitis Antacids* Anti-H2f Operated Lost Antacids* Anti-H2t Operatedt Lost
Yes (n=33) 11(37) 7 (20) 13 (43) 3 9 (35) 4 (15) 13 (50) 4
No (n=74) 44 (60) 19 (26) 10 (14) 1 40 (64) 13 (20) 10 (16) 11
Footnotes as for Table IV.
The relation of initial oesophagitis grade and
basal LOSP with three year therapeutic need for
each patient (Figure) shows that both oesopha-
gitis and low LOSP are good predictors of
outcome. Thus major treatment was required by
19 of 30 patients with and 30 of 73 without
oesophagitis (p=0 040), and by 28 of 45 patients
with LOSP s7mm Hg and 21 of 58 with normal
LOSP (p=0 009). The comparison ofpresenting
features of patients with different treatment
requirements at the three year evaluation (Table
VI) also shows that oesophagitis and low LOSP,
in addition to radiological reflux, were associated
with major therapeutic need.
By multivariate analysis, the following factors
were shown to be independent predictors of
vigorous treatment requirements: low LOSP
(p<0-001), radiological reflux (p=0-028), and
erosive oesophagitis (p=0-031). Respective
positive predictive values, derived from data in
Table V and the Figure, were 0-62, 0-63, and
0-63.
Discussion
In this study 107 consecutive outpatients
with documented GORD were prospectively
evaluated with a clinical score, radiology, endo-
scopy, and manometry. They were subsequently
managed with lifestyle changes plus a stepwise
therapeutic approach and followed up for up to
six years. Patient's satisfaction was the main
factor that influenced treatment adjustments;
thus the success of treatment (symptomatic
remission) was determined by the patients rather
than by their physicians. The results show that a
conservative approach can provide long lasting
remission in many patients and suggest that,
once those with worse GORD are treated with
anti-reflux surgery, the disease tends to run a
TABLE VI Presentingfeatures ofpatients with GORD in relation to treatment requirements at
threeyears
Continuous
anti-H2 or
Conservative anti-reflux
Initialfeatures treatment surgery p Value
Patients (No) 54 49
Sex (M/F) 27/27 23/26
Age (mean (SD) y) 48 (19) 52 (18)
Smokers (No) 17 10
Quit smoking (No (%)) 9 (53) 1 (10)
Obese (No) 17 18
Lost >5 kg (No (%)) 8 (47) 4 (22)
Clinical score (mean (SD)) 6-1 (2 7) 6-7 (2-7)
Hiatus hernia (No (%)) 31 (57) 30 (61)
Radiological reflux (No (%)) 14 (26) 24 (49) 0-016
Erosive oesophagitis (No (%)) 11 (20) 19 (39) 0-040
LOSP (mean (SD) mm Hg) 12-0 (7-1) 7-7 (5 0) <0-001
Stimultaneous peristaltic waves (No (%)) 6 (11) 10 (20)
Distal peristaltic amplitude (mean (SD) mm Hg) 43-3 (15-6) 40-2 (13-2)
Distal amplitude <25 mm Hg (No (%)) 7 (13) 6 (12)
benign course; they also indicate that oesopha-
gitis, radiological reflux, and low LOSP are
independent predictors of more vigorous thera-
peutic need during long term follow up.
Because admission into the study was based on
symptoms and not oesophagitis or abnormal
prolonged pH monitoring, it could be argued
that some patients were not true refluxers. Most
patients with typical reflux symptoms can be
diagnosed reliably, however, by history alone.20
Furthermore, each patient was positive in at least
two of several highly specific tests for GORD.2'
Most patients were studied before the wide-
spread availability of 24 hour oesophageal pH
monitoring; in the few patients in whom it was
used, its positivity had a 90% correlation with
symptoms. This test, however, has not yet been
established as the gold standard for the diagnosis
of GORD.22 24 Our patients had clinically severe
GORD, as shown by the frequency of nocturnal
reflux, respiratory symptoms, and non-cardiac
chest pain, but only 30% had erosive oesopha-
gitis and 10% had complications (strictures or
deep oesophageal ulcer); on the other hand,
clinical scores were similar regardless of
oesophagitis grade. These findings underline the
well known discrepancy between symptomatic
severity and the endoscopic appearance of
oesophagitis in GORD.5
Whereas the clinical, endoscopic, and mano-
metric scores of the patients who were refractory
to medical treatment implied severe GORD,
anti-reflux surgery had excellent results in 22 of
23 patients followed up for a mean of six years
after the procedure. It deserves mention that
these overall good surgical results were obtained
by two surgeons (LG and CP) skilled in the
technique of fundoplication. Reports on the long
term follow up of patients whose surgical repair
was performed by single surgical teams confirm
the long lasting good results of this anti-reflux
procedure.42526
Although neither the clinical severity ofGORD
nor the presence of oesophagitis seem to be
related to increased rates of gastric acid secre-
tion,27 28 it is clear now that profound acid
suppression, such as that provided by the drug
omeprazole, is required for symptom control and
healing of oesophagitis in many patients.929
Had our study not predated the availability of
omeprazole, some patients might not have been
submitted to anti-reflux surgery because of
refractory GORD.
Due to the tendency of GORD to improve
during extended outpatient care (table IV), the
initial response to graded treatment was a good
predictor of treatment needs during long term
follow up only for patients achieving sympto-
matic remission with conservative treatment.
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Thus 80% of those and 67% of patients initially
requiring H2 blockers had a lasting response to
simple modes of treatment, which was shared by
17% of the patients who had been refractory to
short term medical management but did not have
anti-reflux surgery. The results challenge the
presumption that long term intensive treatment
is necessary for most patients with GORD.
Other authors7-'0 have reported that patients
with oesophagitis relapse quickly when pharma-
cological treatment is interrupted. Both selection
of more severe cases and the overlooking of
lifestyle modifications in these studies7'-0 could
explain the differences from our present series.
At all times during prolonged patient care in
our study emphasis was placed on simplistic,
traditional modes of treatment, such as diet
modification, elevation of the bedhead, tobacco,
alcohol and drug restriction, and antacid use. As
recently reviewed,30 these measures are based on
sound physiological principles but are often
neglected in this age of potent acid suppressive
drugs. In our study controllable changes, like
stopping smoking and weight loss, occurred
more often in patients who did well on conserva-
tive treatment (Table VI).
Little is known about factors influencing
therapeutic responses in GORD.729 We did not
carry out tests for alkaline reflux, which can be
associated with complications of oesophagitis or
refractoriness to medical treatment.3' The
logistic regression analysis in our study shows
that a low basal LOSP, the detection of reflux by
barium meal, and the existence of oesophageal
erosions as judged by endoscopy, independently
predict the long term need for sustained pharma-
cological acid suppression or anti-reflux surgery
in GORD. According to their positive predictive
values, the presence of each one of these vari-
ables would correctly predict the long term
course in roughly two out ofevery three patients,
thus their investigation should be clinically use-
ful. The association of low LOSP with vigorous
long term treatment requirements is consistent
with available evidence." 21 27 3233 A potential
explanation for the fact that radiological reflux
had prognostic value independently of LOSP
could be that, as well as a low basal LOSP,
it reflected an increased rate of transient
relaxations of a normotensive lower oesopha-
geal sphincter after the barium meal.4 As
expected,729 another independent predictor of
need for continuous treatment was the presence
of endoscopic oesophagitis at initial evaluation.
Taken together, these results suggest that
refractoriness to conservative treatment in
GORD is due to the severity of the reflux itself.
For such a common disease as GORD, it is
surprising how little is known about the long
term outcome of treated patients. Studies of
patients with oesophagitis followed up for
periods of two to three years under continuous
treatment with antacids32 or H2 blockers with or
without added metoclopramide" indicate that a
significant proportion of patients have frequent
symptomatic relapses when treatment is tapered
off. On the other hand, continuous treatment of
patients with complicated GORD with a combi-
nation of general anti-reflux measures, antacids,
and standard doses of ranitidine is useful in
controlling symptoms for up to two years,
although surgical treatment is more effective.35 A
recent study suggests that most patients with
non-erosive GORD treated with antacids, but
not advised on lifestyle changes, have persisting
symptoms after one year.36 Schindlbeck et al37
have recently reported that less than a quarter of
patients with conventional GORD treated con-
servatively improve after three years; these
patients, however, were not directly followed up
by the authors after diagnosis, and no mention is
made of modifications in lifestyle.37 A different
picture emerges from our study, which shows
that more than half of unselected patients with
GORD do well with simple modes of treatment
for up to six years. Consequently, the clinical
course of GORD under continuous medical
surveillance seems to be more benign than
previously presumed.
The clinical experience gained in this study
supports the notion that conservative treatment
should be tried initially in patients with reflux
symptoms.32' 30 Many patients will be expected
to have a lasting response to this simple, low cost
approach. In non-responding patients, radio-
logical, endoscopic, and manometric findings
have predictive value for the long term outcome
and can help in the early selection of candidates
for anti-reflux surgery or, alternatively, sus-
tained pharmacological acid suppression.
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